Femme et Homme | 65 ans et plus
- | Pays :
- France
- | Organes :
- Myélomes
- | Spécialités :
- Chimiothérapie
- Gériatrie
Extrait
A phase III, randomized, open-label, 3-arm study to determine the efficacy and safety of lénalidomide (REVLIMID) plus low-dose dexamethasone when given until progressive disease or for 18 four-week cycles versus the combination of melphalan, prednisone, and thalidomide given for 12 six-week cycles in patients with previously untreated multiple myeloma who are either 65 years of age or older or not candidates for stem cell transplantation.
Extrait Scientifique
en cours d'intégration;